BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) recommends the use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine for routine wound management in adolescents and adults who require a tetanus toxoid-containing vaccine who were vaccinated ≥5 years earlier with tetanus toxoid, reduced diphtheria toxoid (Td) vaccine, and who have not previously received Tdap.
OBJECTIVE: To estimate the overall budget and health impact of vaccinating individuals presenting for wound management with Tdap instead of Td vaccine, the current standard of care in practices that do not use Tdap for purposes of wound management.
METHODS: A decision-analytic economic model was developed to estimate the expected increase in direct medical costs and the expected number of cases of pertussis avoided associated with the use of Tdap instead of Td vaccine in the wound management setting. Patients eligible for Tdap were aged 10+ years and required a tetanus-containing vaccine. Age-specific wound incidence data and Td and Tdap vaccination rates were taken from the National Health Interview Survey and the National Immunization Survey for the most recent available year. Age-specific pertussis incidence used in this analysis (151 per 100,000 for adolescents, 366 per 100,000 for those aged 20-64 years, and 176 per 100,000 for those aged 65+ years) used reported incidence rates adjusted by a factor of 10 for adolescents and by a factor of 100 for adults, based on assumptions previously made by ACIP to account for underreporting. Vaccine wholesale acquisition costs without federal excise tax were assumed in the base case. Efficacy of vaccination with Tdap in preventing pertussis was based on clinical trial data. Possible herd immunity effects of vaccination were not included in the model. Costs associated with vaccination and treatment of pertussis cases were reported as total annual costs and per-member-per-month (PMPM) costs for hypothetical health plans and for the U.S. population. Aggregate and incremental costs and pertussis cases avoided were presented undiscounted (as recommended for budget-impact analyses) annually and cumulatively over a 3-year time horizon in 2012 U.S. dollars. Scenario analyses were conducted on key parameters, including wound incidence, pertussis incidence, vaccine efficacy and waning protection against pertussis, uptake rates for Tdap, and vaccine prices using alternative data sources or alternative clinically relevant assumptions.
RESULTS: For a health plan with 1 million covered lives aged < 65 years, vaccination with Tdap instead of Td was estimated to cost an additional $132,364 ($0.01 PMPM) in the first year and an additional $368,640 ($0.01 PMPM) cumulatively over 3 years. For a health plan with 1 million
R E S E A R C H • The Centers for Disease Control and Prevention's Advisory
Committee on Immunization Practices currently recommends the use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in routine wound management for adolescents and all adults who require a tetanus toxoid-containing vaccine who were vaccinated ≥ 5 years earlier with tetanus toxoid, reduced diphtheria toxoid (Td) vaccine, and who have not previously received Tdap.
• Coverage rates for Tdap vaccination remain below 80% among adolescents (78.2% in 2011) and adults aged < 65 years (12.5% in 2011) and are negligible among adults aged 65+ years (coverage rate was not reported in 2011 because Tdap has only been recommended for use in this age group since July 2011).
• Several studies have shown that vaccination against pertussis in the form of a Tdap vaccine for adolescents, adults, and the elderly is cost-effective compared with no vaccination.
What is already known about this subject
covered lives aged 65+ years, vaccination with Tdap instead of Td was estimated to cost an additional $201,165 ($0.02 PMPM) in the first year and an additional $549,568 ($0.02 PMPM) cumulatively over 3 years. For the U.S. population aged 10+ years, vaccination with Tdap instead of Td was estimated to result in protection against pertussis for an additional 2.7 million patients with wounds annually and was estimated to cost an additional $121,101,671 to avoid 42,104 cases of pertussis over the 3-year time horizon. Results were sensitive to input parameter values, particularly parameters associated with the number of patients with wounds vaccinated with Tdap (range 2.7 to 5.1 million patients). However, for all of the alternative scenarios tested, the expected increase in PMPM costs ranged from < $0.01 to $0.03.
) and adults aged < 65 years (12.5% in 2011 11 ) and are negligible among adults aged 65+ years (coverage rate was not reported in 2011 because Tdap has only been recommended for use in this age group since July 2011). These differences in coverage rates by age are driven primarily by school entry vaccination requirements that ensure high coverage rates among adolescents. Additionally, Tdap coverage rates among adults may have been historically low as a result of lack of insurance coverage for the vaccine or low reimbursement rates prior to implementation of the Affordable Care Act. 12 Individuals present to the health system for wound management with an estimated annual incidence rate between 0.028 per 100,000 (aged 65+ years) and 0.053 per 100,000 (aged 15-24 years). 13 Thus, the CDC recommendation for the use of Tdap in routine wound management could help to increase the coverage rates for pertussis revaccination in the adolescent and adult populations in the United States.
Vaccination of adolescents, adults, and the elderly against pertussis with a Tdap vaccine has been shown to be costeffective (incremental cost per quality-adjusted life-year gained of < $50,000), compared with no vaccination, in U.S. published studies [14] [15] [16] [17] and in presentations to the Advisory Committee on Immunization Practices (ACIP) at the CDC. 18, 19 The costeffectiveness analyses took a societal perspective that included both direct and indirect costs. In addition to evaluating the cost-effectiveness of introducing Tdap for routine wound management, it is important to understand the potential impact of the new recommendations on the health care expenditures for those responsible for its implementation. In this study, a decision-analytic model was developed to estimate the budget impact and reduction in pertussis cases expected from vaccinating individuals with Tdap instead of Td for routine wound management from the perspective of a health plan and the U.S. population.
■■ Methods Model Structure
A decision-analytic model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA) to estimate the budget impact of substituting Td vaccination with Tdap for individuals presenting for wound management (see Figure 1) . The model was designed to estimate the budget impact and pertussis cases avoided for 2 types of hypothetical health plans: (1) a health plan with 1 million members that includes only individuals aged < 65 years and (2) a health plan with 1 million members that includes only individuals aged 65+ years. The model was also designed to estimate the budget impact and pertussis cases avoided for the U.S. population aged 10+ years. P ertussis is an acute respiratory infection caused by a gram-negative bacterium that typically results in spasmodic paroxysmal coughing bouts ending with an inspiratory whoop sometimes followed with vomiting. For the very young, the elderly, and adults with conditions that put them at risk of complications from any respiratory infection, pertussis can be a serious illness, requiring hospitalization and even resulting in death. 1 Even for those not experiencing severe complications, prolonged periods with paroxysmal coughing bouts may result in multiple visits to a health provider and extended absences from school or work. [1] [2] [3] A combined diphtheria, tetanus, and whole pertussis vaccine was introduced into routine vaccination schedules for infants and young children in the late 1940s, and subsequently, a vaccine containing combined diphtheria, tetanus, and acellular pertussis (DTaP) was introduced in the late 1990s. 1 These vaccination strategies resulted in significant reductions in the annual incidence of pertussis and deaths due to pertussis in the United States, from approximately 200,000 cases per year in the prevaccine era to a low of 1,010 cases reported in 1976. 1 However, there have been subsequent increases in the number of cases (up to 48,277 in 2012 4 ), most commonly in adolescents and adults. 1, 5 A combined tetanus toxoid, reduced-antigen content diphtheria toxoid, and acellular pertussis (Tdap) vaccine was first licensed for single use in adolescents in May 2005, in adults aged 19 to 64 years in June 2005, and in adults aged 65+ years in July 2011. 6 Recommendations by the Centers for Disease Control and Prevention (CDC) for the use of these vaccines in adolescents and adults followed after the license dates. 1 The CDC currently recommends a single dose of Tdap in adolescents and in adults of all ages. 7 In addition, the current CDC recommendations state that "Tdap is preferred to Td vaccination for adults who require a tetanus toxoid-containing vaccine as part of wound management, who have received a Td ≥ 5 years previously, and who have not previously received Tdap." 7 • This study estimates the budget impact of vaccinating individuals presenting to the health system for wound management with Tdap instead of Td, as well as the likely clinical outcomes from a health plan or U.S. population perspective.
• Our base-case findings provide evidence that vaccination of adolescents and adults with Tdap instead of Td for wound management results in an annual budget impact ranging from $113,793 to $201,165 ($0.01-$0.02 per member per month) for health plans with 1 million members.
• This study estimated that a Tdap vaccination strategy targeting patients with wounds requiring a tetanus-containing vaccine would impact between 2.7 and 5.1 million people each year in the United States.
Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases
The time horizon for the budget-impact analysis was 3 years, with each annual cohort representing individuals presenting with first-time or previous wounds. Each annual cohort was monitored for pertussis cases for the entire time period of the model. In other words, those presenting in the first year were tracked during the year of vaccination and the following 2 years; those presenting in the second year were tracked during the year of vaccination and the following year; and those presenting in the third year were tracked only in the year of vaccination. This approach captures all costs relating to vaccination and pertussis disease for the 2 base-case scenarios for the model time horizon but does not capture the pertussis disease costs for the 3 vaccinated cohorts that persisted beyond the 3-year model time horizon.
The model captured only the direct effects of pertussis vaccination efficacy on those vaccinated and did not estimate herd immunity effects on unvaccinated contacts. Waning of vaccine efficacy and protection against pertussis during the first 3 years was included in the model, and alternative values for the level of waning (i.e., drop in efficacy) were tested in a scenario analysis using new data for adolescents vaccinated with acellular pertussis vaccination as part of their primary vaccine 20 Exclusion of herd immunity and inclusion of vaccine waning were conservative assumptions for estimating the budget impact of Tdap in reducing the estimated health care costs associated with the estimated avoided cases of pertussis.
Eligible Population for Tdap Vaccine (Number of Wounds)
The annual number of wounds eligible for Tdap was derived using annual wound incidence data from the 2007 U.S. National Health Interview Survey, 13 and self-reported data on vaccination with Td or Tdap from the 2011 National Immunization Survey among adolescents 10 and the 2011 National Health Interview Survey among adults.
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To estimate the annual number of patients with open wounds eligible for Tdap, a series of filters were applied on the population of a hypothetical health plan or on the total U.S. population as follows (see Appendices [available in online article] for detailed description of data and calculations used to estimate percentage of patients with open wounds eligible for Tdap):
• Step 1. The modeled population was divided into 3 age groups-10 to 19, 20 to 64, and 65+ years-in order to use age-specific pertussis incidence and wound incidence data, both of which are highly age-dependent. The age distribution within the United States for 2010 was used for the U.S. population analysis. 21 The U.S. age distribution for 2010 for those under 65 years also was applied to health plans with individuals aged < 65 years to calculate the percentage of individuals who were aged 10 to 19 years and 20 to 64 years.
• Step 2. The number of patients with a wound requiring tetanus-containing vaccination (including first-time or recurrent wounds) was estimated using age-specific annual wound incidence data to fit the age groups in the model. 13 Wounds requiring tetanus vaccine were those reported as "open" wounds. Wounds reported as "other"-including fire-, burn-, or scald-related episodes; animal or insect bites; machinery accidents; and other but not specified episodes where a tetanus booster vaccination might be consideredwere included in the scenario analyses.
• Step 3. The number of people who either had not received a Td vaccine within the last 5 years or had never been vaccinated with a Tdap vaccine was estimated among individuals with wounds using national survey data of vaccination rates among adolescents (National Immunization SurveyTeen
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) and adults (National Health Interview Survey 11 ; see Appendices A, B, and C, available in online article). Although the vaccination survey data were among the general U.S. population, Td and Tdap vaccination rates among those with wounds were assumed to be similar to those among the general U.S. population.
• Step 4. The number of patients with open wounds eligible for vaccination with a Tdap vaccine was calculated and aggregated across age groups (see Table 1 and Appendix D, available in online article).
All patients with wounds eligible for vaccination with Tdap were assumed to accept vaccination with either Td or Tdap. Two base-case scenarios were compared: Scenario 1, all individuals were vaccinated with Td, and Scenario 2, all individuals were vaccinated with Tdap.
Although a vaccination uptake rate of 100% and market share assumptions of either 100% Td and 0% Tdap or vice versa is unlikely to reflect the real-world situation, vaccination acceptance rates for wound management are largely unknown, and this methodology allows for the estimation of the upper bound of the budget impact and pertussis cases avoided when comparing vaccination with Tdap instead of Td.
Pertussis Cases
Pertussis cases were estimated according to disease severity to accurately estimate pertussis-related mortality and costs. Based on data available in the literature and definitions used by previous models, the following definitions were used for mild, moderate, and severe cases:
• Mild: cases without paroxysmal cough; reported cases require 1 physician visit in an outpatient setting and no treatment.
• Moderate: cases with paroxysmal cough with or without other complications (including cyanosis, vomiting, urinary incontinence) requiring medical care and treatment in an outpatient setting (but not requiring hospitalization).
• Severe: cases with paroxysmal cough and other serious complications (including pneumonia) requiring hospitalization. 
Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases Deaths
The model accounted for mortality due to pertussis as well as allcause mortality. Pertussis-related death was included for severe cases of disease only. Case fatality rates for the 3 age groups were derived from data used by a previous model (Table 2) . 15 All-cause mortality was estimated using age-specific U.S. mortality rates.
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Costs
Costs were estimated for vaccine acquisition, vaccine-related adverse events, and treatment of pertussis (Table 2 ). In the base-case analysis, vaccine wholesale acquisition costs minus federal excise tax were used, using values for BOOSTRIx and generic Td as representative of Tdap and Td vaccines generally. 25 In a scenario analysis, the lower vaccine costs were tested using contracted public prices ($14.51 for Td and $28.16 for Tdap for children; $11.88 for Td and $22.71 for Tdap for adults) based on the CDC vaccine price list. 26 A 10% higher price for Tdap also was tested. Costs for treating vaccine-related adverse events were estimated for the Td and the Tdap vaccines, based on the incidence rates and costs for treating these events used in a previous cost-effectiveness analysis of pertussis vaccine. 14 Vaccine administration costs were not included.
Costs for treatment of mild, moderate, or severe cases of pertussis were consistent with the definitions presented previously for incidence of reported pertussis cases by severity type. The cost for treating a mild case of pertussis was assumed to be equivalent to the cost of 1 physician visit; the cost for treating a moderate case of pertussis was based on average costs for outpatient cases used by the CDC ACIP 18 ; the cost for treating a severe case of pertussis was based on the cost of hospitalized cases (Table 2) . 27 Costs by age were explored, but there was from 97 to 699 cases per 100,000 person-years, or approximately 10 to 77 times higher than the incidence of disease reported by passive surveillance data (8.97 cases per 100,000 person-years). 22 Therefore, to estimate the number of cases of pertussis and to account for underreporting of pertussis cases in the United States, the most recent data on reported incidence of pertussis by age from the CDC were adjusted by a factor of 10 for adolescents and by a factor of 100 for adults in the basecase analysis based on assumptions previously made by the CDC ACIP (Table 2) . 18, 22 Higher adjustment factors were tested in a scenario analysis, resulting in incidence values ranging from 151 (base case) to 753 per 100,000 for adolescents, 366 (base case) to 731 per 100,000 for those aged 20-64 years, and 176 (base case) to 352 per 100,000 for those aged 65+ years. When disease incidence is adjusted upward in the model to account for underreporting of passive surveillance data, we assumed that all levels of severity of disease are equally underreported. This assumption is consistent with data seen in prospective surveillance studies (using the definitions outlined previously). 23 For each base-case scenario, the number of patients with wounds vaccinated (by age) was multiplied by pertussis incidence (by age) and by vaccine efficacy against pertussis (0% for Td; 89% for Tdap). 8 Waning of vaccine efficacy was included, assuming protection against pertussis lasted for 8 years and declined exponentially each year, such that efficacy dropped from 89% in the first year to 79% in the second year and 69% in the third year for the 3-year model time horizon (Table 2) . In scenario analyses, lower baseline efficacy and a larger decrease in efficacy was tested based on recent data from the CDC: 75%, 56%, and 39% efficacy in the first, second, and third year, respectively. 
Model Input Parameters (continued)
Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases a lack of data in the published literature on differential costs by age, particularly for mild and moderate cases of pertussis. Thus, costs differed by severity of disease but not by age.
The costs of treating long-term complications of pertussis, including neurological sequelae, were excluded because of the short time horizon. Excluding these costs was conservative because inclusion would lead to greater cost savings per case of pertussis avoided with protection from Tdap and a lower budget impact. All costs related to wound management, including vaccine administration costs, were not included because they are equal for both vaccines and were considered beyond the scope of this analysis.
When necessary, all costs were inflated to 2012 U.S. dollars using the medical care component of the Consumer Price Index.
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Model Outcomes
For each base-case scenario, the number of patients with wounds who were vaccinated, number of cases of pertussis, cost of treating pertussis cases, vaccine costs, and vaccinerelated adverse event costs were calculated on an annual basis and calculated cumulatively over the 3-year time horizon. The aggregate and incremental undiscounted health outcomes and cost outcomes are shown annually and cumulatively for 2 types of health plans (those with people aged < 65 years and those with people aged 65+ years) and for the U.S. population aged 10+ years. Costs are reported as total annual costs and per-member-per-month (PMPM) costs because PMPM costs represent the impact vaccination has on the insurance premiums for the health plans. Outcomes are undiscounted, as recommended for budget-impact analyses.
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Sensitivity Analyses
A series of scenario analyses were conducted to test how changing specific input parameter values or model assumptions would affect results. All of the input parameters in the model were varied using alternative data sources or alternative clinically relevant assumptions. Scenarios with the largest (positive or negative) impact on either total medical costs or cases of pertussis cases avoided are presented. Alternative scenarios are presented for the following key parameters: annual number of patients with wounds eligible for vaccination with Tdap, uptake rates for Tdap, annual pertussis incidence, waning of Tdap efficacy (i.e., protection against pertussis), and prices for Td and Tdap vaccines.
For each of the scenario analyses, the number of pertussis cases avoided and the increase in total medical costs are shown cumulatively over the 3-year time horizon for the 2 types of health plans and for the U.S. population.
■■ Results
For a health plan with 1 million members aged <65 years, an estimated 8,240 patients with open wounds were eligible for Tdap vaccination each year (Table 1) . Vaccination with Tdap instead of Td for wound management was estimated to increase annual medical costs (additional costs due to vaccination minus reduced costs for treating pertussis) in year 1 from $160,227 to $292,641 for a total increase of $132,364 or an increase in PMPM costs of $0.01 (Table 3 ). The estimated increase in medical costs was slightly lower in year 2 ($122,484) and year 3 ($113,793), with an estimated increase in PMPM costs of $0.01. Over the 3-year time horizon, an estimated 141 cases of pertussis were avoided if people presenting with wounds were vaccinated with Tdap instead of Td.
For a health plan with 1 million members aged 65+ years, an estimated 12,891 patients with open wounds were eligible for Tdap vaccination each year (Table 1) . Vaccination with Tdap instead of Td was estimated to increase annual medical costs in year 1 from $257,236 to $458,401 for a total increase of $201,165 or an increase in PMPM costs of $0.02 ( the results were most sensitive were similar for the 2 types of health plans and the U.S. population: more wounds eligible for Tdap by including both open wounds and other wounds led to the largest increase in cumulative direct medical costs (ranging from 57% to 93% higher than the base case); lower uptake rates for Tdap led to the largest decrease in cumulative direct medical costs (ranging from 48% to 49% lower than the base case); and higher pertussis incidence also reduced the cumulative direct medical costs (ranging from 18% to 22% lower than the base case; Table 5 ).
For all of the scenarios tested, the increase in PMPM costs ranged from < $0.01 to $0.02 for health plans for ages < 65 years and ranged from < $0.01 to $0.03 for health plans for ages 65+ years. For the U.S. analysis, the cumulative increase in direct medical costs over the 3-year time horizon ranged from $62.1 million to $226.0 million, and the cumulative number of pertussis cases avoided ranged from 17,919 to 88,724 (Table 5 ).
years. Over the 3-year time horizon, an estimated 109 cases of pertussis were avoided.
For the U.S. population aged 10+ years, an estimated 2,731,407 patients with open wounds were eligible for Tdap vaccination each year (Table 1) . Vaccination with Tdap instead of Td was estimated to increase annual medical costs by $43,637,377 in year 1, $40,220,398 in year 2, and $37,243,896 in year 3 (Table 4 ). Over the 3-year time horizon, the expected number of pertussis cases avoided among people aged 10+ years in the United States was 42,104, with an estimated additional expenditure of $121,101,671 or approximately $2,876 per case avoided.
Scenario analyses showed that the results (i.e., cumulative direct medical costs or cases avoided over the 3-year time horizon) were sensitive to the number of patients with wounds vaccinated with Tdap, the adjustment factor to account for underreporting of pertussis, and the incremental price difference between Td and Tdap vaccines. The parameters to which 
U.S. Annual Population Costs and Clinical Outcomes over a 3-Year Time Horizon (2012 U.S. Dollars)
Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases
PMPM), with 141 pertussis cases avoided per 1 million health plan members aged < 65 years. Tdap was estimated to cost an additional $549,568 ($0.01 to $0.02 PMPM), with 109 pertussis cases avoided per 1 million health plan members aged 65+ years. Results for the analysis of the U.S. population aged 10+ years showed that over the 3-year time horizon the estimated expected number of pertussis cases avoided was 42,104, at a cost of approximately $2,876 per case avoided.
This cost per case avoided, which is based on an assumed pertussis incidence of 151, 366, and 176 cases per 100,000 people aged 10-19, 20-64, and 65+ years, respectively, is similar to cost-effectiveness ratios found by other studies using similar ranges for pertussis incidence (ranging from $830 to $2,220 per case avoided among adolescents and from $538 to $1,966 per case avoided among people aged 65+ for pertussis
■■ Discussion
Vaccination with Tdap instead of Td for patients presenting to the health system with a wound requiring tetanus vaccine and who are eligible for Tdap is estimated to lead to an increase of < $0.01 to $0.03 in health plan PMPM costs for the health plan with all members aged < 65 years and for the health plan with all members aged 65+ years. Direct medical costs are expected to increase each year, but the increase in costs (i.e., budget impact) is expected to be lower in year 2 and year 3 as compared with year 1. This is because the number of avoided cases of pertussis and the associated offsetting cost savings in medical costs are expected to increase each year due to the increase in the cumulative number of people vaccinated and protected against pertussis. Over 3 years, vaccination with Tdap was estimated to cost an additional $368,640 ($0.01 However, these cost-effectiveness ratios are not directly comparable because our budget-impact analysis used undiscounted direct medical costs over a short (3-year) time horizon, whereas cost-effectiveness analyses typically include direct and indirect costs discounted over a long (i.e., lifetime) time horizon to estimate the economic efficiency of a new intervention from a societal perspective.
The estimated total costs and incremental costs are greater for health plans with individuals aged 65+ years than costs for those with individuals aged < 65 years because of the number of unvaccinated people in the older age group and subsequently the greater number of patients with wounds who are vaccinated (12,891 vs. 8,240 patients with wounds per year). Although people aged 65+ years have a higher likelihood of developing a severe case of pertussis and thus an overall higher cost of treatment, pertussis costs in this age group are lower because the estimated number of cases of pertussis avoided is lower for health plans including individuals aged 65+ years (109 vs. 141 avoided cases), despite the higher number of vaccinated individuals. This finding can be explained by the lower incidence of pertussis among individuals aged 65+ years when compared with younger individuals.
For people aged 65+ years, Tdap is typically covered under Medicare Part D instead of under Medicare Part B. A recent survey of U.S. physicians found that financial barriers, such as lack of reimbursement for a vaccine, low reimbursement rates for a vaccine, or coverage under Medicare Part D (which typically includes high out-of-pocket costs), were the most commonly reported reasons for low vaccination rates among adults. 12 Because of low vaccination rates, ACIP recommends physicians vaccinate persons aged 65+ years with either Tdap vaccine they have available so as not to "miss an opportunity to vaccinate." 7 Although the Affordable Care Act mandated that private health plans cover all vaccines recommended by ACIP without requiring a copayment, eliminating the financial barrier for individuals with private insurance, this law does not impact Medicare coverage policies. Since the burden of pertussis remains a concern and vaccine coverage rates remain suboptimal in this age group, coverage of Tdap vaccine for routine wound management by Medicare Part B and vaccination with either Tdap vaccine for patients with wounds could be considered as strategies for increasing pertussis vaccine coverage among people aged 65+ years.
Results of this study were sensitive to input parameter values, particularly parameters associated with the number of patients with wounds vaccinated with Tdap. This study estimated that a Tdap vaccination strategy targeting patients with wounds requiring a tetanus-containing vaccine would impact between 2.7 and 5.1 million people in the United States, which is similar to or substantially smaller than other target populations for Tdap vaccination. 16 The estimated increases in annual medical costs and cases of pertussis avoided are both a function of the number of patients with wounds eligible for and vaccinated with Tdap (i.e., as the number of patients with wounds vaccinated with Tdap increases, annual medical costs and cases of pertussis avoided increase). Therefore, it is not surprising that the results were most sensitive to parameters that directly impacted the number of patients with wounds vaccinated with Tdap: the annual incidence of wounds (or specifically whether wounds categorized as "other" were included in addition to open wounds) and the uptake rate for Tdap. Lower vaccine efficacy and greater waning of efficacy over time were tested in scenario analyses using recent real-world effectiveness data 20 ; however, results were more sensitive to other input parameters previously discussed.
Despite the wide range of our results, they likely overestimate the expected increase in medical costs and underestimate the benefits of Tdap for 2 reasons. First, assuming that Tdap provides protection against pertussis for more than 3 years, the impact on pertussis cases prevented each year will increase each year as long as those in the first vaccinated cohort maintain their protection. Once that protection is lost, a steady-state number of pertussis cases avoided may be reached. Second, the analysis of the benefits of the vaccine program for routine wound management does not include the possible herd immunity benefits for reduced cases of pertussis in people who have contact with those who receive Tdap for wound management and who do not have active protection against pertussis.
The strength of the current analysis is that it is the first to provide estimates of the expected financial cost (i.e., affordability) and the expected number of pertussis cases avoided from a vaccination strategy using the Tdap vaccine in routine wound management. Such estimates are valuable to health care decision makers who are responsible for health plan or national budgets. To assist with this, the results have been presented from the health plan and the U.S. population perspectives.
Limitations
This analysis has several limitations, particularly with respect to the input data used to populate the model. The National Health Interview Survey is a self-reported survey on the incidence of wounds, which introduces reporting bias. However, the strength of this source is that it captures all patients with wounds who received health care (i.e., incurred some sort of direct medical cost). Other approaches, such as using claims databases to identify patients with wounds by the International Classification of Diseases, Ninth Revision, Clinical Modification codes, would require piecing together multiple databases to account for patients with wounds presenting in various health settings (e.g., outpatient setting, inpatient setting, emergency department, urgent care facility), which could lead to double counting or an overestimate. Given the uncertainty in the number of patients with wounds requiring tetanus vaccination each Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases year and the sensitivity of our study's results to this parameter, future analyses using alternative methods for estimating wound incidence may be warranted to improve the precision around our study's estimates.
Another limitation in the model is the considerable uncertainty about 2 input values that make the most difference to the budget impact of Tdap. First, the budget impact of Tdap decreases when the annual incidence of pertussis is higher. There is considerable uncertainty in the annual pertussis incidence data, especially in the proportion of cases that are correctly diagnosed and/or reported. Incidence rates ranging from 151 to 753 per 100,000 for adolescents and ranging from 176 to 731 per 100,000 for adults were explored. Second, the budget impact of Tdap increases when the total number of patients with wounds for which a tetanus booster may be considered is higher. Age-specific annual wound incidence data are reported in 2 categories: open wounds-management of which would almost certainly include the recommendation for a tetanus booster vaccination in patients without a recent booster vaccination (3.0 million)-and other wounds-including fire-, burn-, or scald-related episodes; animal or insect bites; machinery accidents; and other but not specified episodes (2.6 million)-where a tetanus booster vaccination might be considered (see Appendix E, available in online article). Thus, there is considerable uncertainty about the total number of patients with wounds each year for which a tetanus booster vaccination might be recommended.
Long-term complications of pertussis, including encephalopathy, were not included in the model. Not including the costs of treating long-term pertussis-related disabilities leads to an underestimate in the savings from Tdap vaccination and subsequently an overestimate in the budget impact. However, because of the extremely low incidence of long-term disabilities requiring treatment (estimated as 0.02%-0.07% of pertussis cases 15, 30 ) and because of the short time frame of this analysis, these cost savings are assumed to be negligible.
It should be noted that costs and efficacy values used in this analysis were specific to BOOSTRIx for Tdap. In the United States, there are multiple generics for Td and 2 Tdap brands (BOOSTRIx and Adacel); using different prices for each of these inputs would affect the results. However, findings were consistent in a scenario analysis that used costs and efficacy associated with Adacel instead of BOOSTRIx (not reported here), indicating that results from the current study may be applicable to Tdap vaccines in general.
The use of a simple Microsoft Excel model to estimate the budget impact did not allow us to include possible herd immunity effects that are a result of substituting Tdap for Td in patients eligible for Tdap when presenting for management of a wound. Thus, the impact of increasing vaccine coverage rates on pertussis cases is likely underestimated.
■■ Conclusions
The current study estimated that vaccination of the U.S. population aged 10+ years with Tdap instead of Td for routine wound management would impact between 2.7 and 5.1 million people with wounds annually. Over a 3-year time horizon, this vaccination strategy is expected to result in 42,104 cases of pertussis avoided at a cost of approximately $2,876 per case avoided. For hypothetical health plans, this translates to an additional cost of $368,640 per 1 million members aged < 65 years and an additional cost of $549,568 per 1 million members aged 65+ years (< $0.01 to $0.03 PMPM). Results were sensitive to input parameter values, particularly parameters associated with the number of patients with wounds vaccinated with Tdap. Vaccination with Tdap for routine wound management could be considered as another strategy to help address the pertussis public health concern in the United States. Future analyses using alternative methods for estimating wound incidence could improve the precision around the estimated budget and health impact of this vaccination strategy to confirm its affordability.
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Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases
The following appendices provide additional details on the tetanus toxoid and reduced diphtheria toxoid (Td) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination rates as reported by 2 nationally representative U.S. surveys: the National Immunization Survey-Teen (NIS-Teen) and the National Health Interview Survey (NHIS). Appendix A presents the vaccination rates for Td and Tdap for adolescents as reported by NIS-Teen. Appendix B presents the vaccination rates for Td and Tdap for adults as reported by the NHIS. Appendix C presents the Tdap vaccination rates among adults aged 19 to 64 years who received a tetanus vaccination. Appendix D describes the calculations and assumption we made to estimate the annual percentage of patients with wounds who were eligible for Tdap vaccination for the 3 age groups in our model (10 to 19 years, 20 to 64 years, and 65+ years) and summarizes the values used in the base-case and sensitivity analyses. 
APPEnDIx E
Wound Descriptive Statistics and Pertussis Incidence, by Age Group
In Approach 2, we simply excluded all patients who reported receiving Td or Tdap in the past 10 years. This approach yielded 35.7% of patients eligible for Tdap, which was an underestimate because it excluded patients who could have received Td vaccine 5 to 10 years ago and who technically would be eligible for Tdap.
Approach 1 was used in the base-case analysis, and Approach 2 was used in sensitivity analysis.
Percentage of 65+ Year-Olds Eligible for Tdap Vaccination (Appendix B):
• First, we assumed that no one aged 65+ years (i.e., 0.0%) received Tdap because it was not indicated or recommended in this population until 2012, which is the year of our analysis. Next, we assumed that patients who reported receiving Td were vaccinated uniformly over the 10-year time period. Given that 54.4% of patients aged 65+ years reported receiving Td in the past 10 years, we assumed each year there was a uniform percentage of patients (i.e., 5.44% of patients) vaccinated with Td each year. Thus, 27.2% of patients were vaccinated with Td within the past 5 years and not eligible for Tdap. This approach yielded 72.8% of patients aged 65+ years eligible for Tdap in Approach 1. In Approach 2, we simply excluded all patients who reported receiving Td in the past 10 years. Approach 1 was used in the base-case analysis, and Approach 2 was used in sensitivity analysis.
Underlying Assumptions to Estimate the Percentage Eligible for Tdap Vaccination for Wound Management
For all age groups, we made the underlying assumption that the percentage of patients who reported receiving Td or Tdap vaccine from the general population was equivalent to the percentage of patients among the wound population. This was a simplifying assumption that was necessary in the absence of data specifically among patients with wounds.
